Growth Hormone Therapy For Various Short Stature
نویسندگان
چکیده
منابع مشابه
Short stature in Noonan syndrome: response to growth hormone therapy.
BACKGROUND Growth hormone (GH) has been used to promote growth in both the short and long term in a number of dysmorphic syndromes, including Turner syndrome. As this condition shares many clinical features with Noonan syndrome, it would seem logical to treat the latter group with GH. AIMS To assess the short and long term response to GH therapy in patients with Noonan syndrome. METHODS Ana...
متن کاملParent requests growth hormone for child with idiopathic short stature.
CASE Cody was always a short child with stature at the 5th percentile of a standard growth curve since he was a toddler. His weight was between the 10th and 25th percentiles. Developmental milestones and early learning achievement were normal. He played in a youth soccer league from 8 to 10 years of age, but he was not enthusiastic about group sports. In middle school, Cody excelled in the scie...
متن کاملEstimated cost-effectiveness of growth hormone therapy for idiopathic short stature.
OBJECTIVE To estimate the cost-effectiveness of growth hormone (GH) therapy for idiopathic short stature (ISS). DESIGN Cost-effectiveness analysis. SETTING Decision model. PATIENTS A cohort of 10-year-old prepubertal boys with ISS treated with GH. INTERVENTIONS Comparison of children treated for 5 years with GH therapy vs children receiving no intervention. MAIN OUTCOME MEASURES Incre...
متن کاملThe Northern Ireland experience of growth hormone therapy for short stature.
In 1967 the first patient in Northern Ireland commenced growth hormone treatment for short stature. By the end of December 1988 a total of 89 patients had been treated. Thirty-two had idiopathic isolated growth hormone deficiency, an incidence of 1.5 new cases per year (in a population of 1.5 million with approximately 30,000 births per year). Since 1967 the mean age at starting treatment has f...
متن کاملGrowth hormone and noonan syndrome: update in dysfunctional signaling aspects and in therapy for short stature
Short stature is a frequent feature of Noonan syndrome (NS), a disease caused by mutations of genes encoding components of the Ras/mitogen-activated protein kinases (MAPK) signalling pathway. To date numerous patients have been treated with growth hormone (GH) in various countries. However this treatment is still controversial, as its efficacy is a matter of debate. The final height gain of GH ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Tepecik Education and Research Hospital
سال: 1993
ISSN: 1305-7073
DOI: 10.5222/terh.1993.85594